About Stephen Rubino, PhD

Dr. David Portman

Dr. Stephen Rubino is currently chief business & strategy officer at Omega Therapeutics, a genomic medicine company in Cambridge, Massachusetts, and a board director at Ilkos Therapeutics. He brings over 30 years of pharmaceutical leadership experience to the Sermonix board, with emphasis in the areas of commercial operations, pharmaceutical strategy, business development and licensing, and investor relations.

Dr. Rubino has also served Novartis Pharmaceuticals in a wide range of roles and therapeutic areas, the last of which was as global head of business development and new product marketing, responsible for developing and building the product pipeline for Novartis’ Cell & Gene Therapies Unit. Prior to Novartis, Dr. Rubino worked for Schering-Plough (Merck) where his last role was head of the Global Solid Tumor Oncology & Autoimmune Business Unit, responsible for the licensing and launch of Remicade, as well as the launch and commercialization of several global oncology brands. Dr. Rubino received his doctorate from Weill Cornell University and his MBA from Baruch University.